Search | Clinical Trials Finder

Conditions: Encephalomyelitis, Myalgic, Chronic Fatigue Syndrome, Chronic Fatigue Disorder, Chronic Fatigue and Immune Dysfunction Syndrome, Myalgic Encephalomyelitis, Postviral Fatigue Syndrome, Systemic Exertion Intolerance Disease, Infectious Mononucleosis-Like Syndrome, Chronic, Chronic Fatigue-Fibromyalgia Syndrome
Interventions: Bupivacaine Injection; Drug
Lead sponsor: Neuroversion, Inc.; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Anchorage, Alaska

Conditions: Gulf War Illness, Persian Gulf Syndrome
Interventions: Submaximal bicycle exercise stress tests performed 24 hr apart; Diagnostic Test
Lead sponsor: Georgetown University; Other
Eligibility: 38 Years to 86 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Muscle Weakness
Interventions: 3-4 Diaminopyridine; Drug
Lead sponsor: Jeffrey A. Cohen, MD; Other
Eligibility: 45 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Juvenile Primary Fibromyalgia Syndrome (JPFS), Fibromyalgia
Interventions: Fluoxetine; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 13 Years to 18 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Temporomandibular Disorder
Interventions: Cervical Spine Thrust Joint Manipulation, Cervical Spine Sham Manipulation, Home Program, Suboccipital Release; Other
Lead sponsor: Bradley University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Peoria, Illinois • Washington, Illinois

Conditions: Mitochondrial Myopathies, Mitochondrial Pathology, Mitochondrial DNA Mutation, Mitochondrial Diseases, Mitochondrial DNA Deletion, Mitochondrial DNA Depletion, Mitochondrial Metabolism Defect, Mitochondrial Complex I Deficiency
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 9
States / cities: San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 6 more

Conditions: Persian Gulf Syndrome
Interventions: Carnosine, Placebo; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 34 Years to 82 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Medically Unexplained Chronic Fatigue, Chronic Fatigue Syndrome
Interventions: Cognitive-behavioral self-management, Symptom monitoring; Behavioral
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Primary Mitochondrial Disease
Interventions: elamipretide; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: San Diego, California • Boston, Massachusetts • Akron, Ohio + 1 more

Conditions: Childhood Depression, Childhood Anxiety, Pediatric Pain, Migraines, ADHD, Pediatric Stomach Pain, Musculoskeletal Pain
Interventions: Integrative Coping Group; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 10 Years to 12 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Fibromyalgia
Interventions: Duloxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 13 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Phoenix, Arizona • Fairfield, Connecticut • St Louis, Missouri + 6 more

Conditions: Mitochondrial Diseases, Mitochondrial Myopathies, Mitochondrial Encephalomyopathies, MELAS, MERRF
Interventions: Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN); Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Familial Dilated Cardiomyopathy
Interventions: danicamtiv; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 12
States / cities: La Jolla, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more

Conditions: Medial Tibial Stress Syndrome
Interventions: Acupuncture, Home Exercise Program; Other
Lead sponsor: Eglin AFB Regional Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Eglin Air Force Base, Florida

Conditions: Myalgia, Hypercholesterolemia, Hyperlipidemia
Interventions: PPD10558, Atorvastatin, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 67
States / cities: Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more

Conditions: Fatigue Syndrome, Chronic, Healthy, Mood Disorders
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fibromyalgia
Interventions: Duloxetine, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 26
States / cities: Phoenix, Arizona • Loma Linda, California • National City, California + 23 more

Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions: Not listed
Lead sponsor: Global Healthy Living Foundation; Other
Eligibility: 19 Years and older
Enrollment: 40,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Upper Nyack, New York

Conditions: Primary Fibromyalgia
Interventions: GRT9906, Placebo; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 6
States / cities: DeLand, Florida • Charlotte, North Carolina • Medford, Oregon + 2 more

Conditions: Temporomandibular Disorder (TMD)
Interventions: SPM Precursor-Enriched Marine Lipid Supplement, Medium-Chain Triglyceride Supplement; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Primary Mitochondrial Myopathy
Interventions: elamipretide, placebo comparator, elamipretide open label treatment; Combination Product
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: La Jolla, California • Palo Alto, California • Aurora, Colorado + 9 more

Conditions: SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 110 Years
Enrollment: 114 participants
Timeline: 1995 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Chronic Fatigue Syndrome, Myalgic Encephalomyelitis, Exercise Intolerance, Dysautonomia, Low Ventricular Filling Pressures (Preload Failure), Postural Orthostatic Tachycardia Syndrome, Orthostatic Hypotension, Fibromyalgia
Interventions: Pyridostigmine Bromide, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fibromyalgia
Interventions: Pregabalin; Drug
Lead sponsor: Newton-Wellesley Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Newton, Massachusetts

Search by objective public record fields.

Effect of Stellate Ganglion Block on ME/CFS

Exercise in Gulf War Illness (GWI)

Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)

Safety and Efficacy of Fluoxetine in Juvenile Fibromyalgia

Cervical Spine Thrust Joint Manipulation for Temporomandibular Disorder

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)

Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)

Fatigue Self-Management in Primary Care

Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

Integrative Coping Group for Children

A Study for Adolescents With Fibromyalgia Syndrome

Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).

Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

Acupuncture for Medial Tibial Stress Syndrome in the Primary Care Setting

Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)

Study of the Hypothalmic-Pituitary-Adrenal (HPA) Axis and Its Role in Major Depression

A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome

PatientSpot Formerly Known as ArthritisPower

Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia

Marine Lipids Ease Painful TMD

A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Fibromyalgia of Less Than One Year Duration. Study of Pregabalin